FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160104303> ?p ?o ?g. }

• W3160104303 endingPage "e1016" @default.
• W3160104303 startingPage "e1008" @default.
• W3160104303 abstract "There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi.This prospective, single-arm, non-randomised phase 1/2 clinical trial was done at Kamuzu Central Hospital Cancer Clinic (Lilongwe, Malawi). Eligible patients were adults (aged 18-60 years) with newly diagnosed DLBCL, an Eastern Cooperative Oncology Group performance status of 0-2, a CD4 count of 100 cells per μL or higher (if HIV-positive), measurable disease by physical examination, an absolute neutrophil count of 1000 × 109 cells per L or higher, a platelet count of 100 × 109 platelets per L or higher, a serum creatinine concentration of 132·60 μmol/L or less, a total bilirubin concentration of 34·21 μmol/L or less, a negative urine pregnancy test in women of childbearing potential, and no previous cytotoxic therapy. Pregnant or breastfeeding women, and individuals with CNS involvement from DLBCL, chronic hepatitis B infection (unless they were receiving tenofovir plus lamivudine), or any other comorbidities that would compromise the protocol objectives were excluded. Eligible patients received intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum 2 mg/m2), and oral prednisone 100 mg or an equivalent drug every 21 days for up to six cycles. HIV-positive patients received concurrent ART. The primary outcome was the proportion of patients with National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4 non-haematological toxic effects or treatment-related deaths after six cycles of treatment. Secondary efficacy outcomes included the proportion of patients with a complete response after six cycles of treatment, and progression-free survival and overall survival at 12 months and 24 months. This trial is registered with ClinicalTrials.gov, NCT02660710.Between Aug 1, 2016, and July 31, 2019, 76 patients were screened, of whom 37 were eligible for the study and received R-CHOP. The median age of patients was 44 years (IQR 39-49) and 16 (43%) were women. Of all 37 patients, 20 (54%) had stage III or IV DLBCL, and the age-adjusted international prognostic index was 2 or higher in 25 (68%) patients. 27 (73%) patients were HIV-positive, with a median CD4 count of 208 cells per μL (IQR 144-422), and 21 (78%) patients were receiving ART at enrolment. Patients completed a median of six cycles (IQR 4-6). Grade 3 or 4 non-haematological toxic effects were reported in 12 (32% [95% CI 19-49]) patients, the most common of which was infection (nine [24%] patients). Of 16 (43%) deaths, ten were due to progression of DLBCL, four were due to treatment-related complications, and two were due to other causes, yielding a treatment-related mortality of 11% (95% CI 4-26%). Grade 3 or 4 neutropenia was observed in 26 (70%) patients, and grade 3 or 4 anaemia was observed in 11 (29%) patients. A total of 22 (59%) patients had a complete response. Overall survival was 68% (95% CI 50-80) at 12 months and 55% (37-70) at 24 months, and progression-free survival was 59% (42-73) at 12 months and 53% (35-68) at 24 months.R-CHOP could be feasible, safe, and efficacious in patients with DLBCL in Malawi. This is the first completed clinical trial on DLBCL focused on sub-Saharan African populations. Given the paucity of data on treatment of DLBCL from this region, these results could inform emerging cancer treatment programmes in sub-Saharan Africa.The University of North Carolina Lineberger Comprehensive Cancer Center." @default.
• W3160104303 created "2021-05-24" @default.
• W3160104303 creator A5006925940 @default.
• W3160104303 creator A5007336043 @default.
• W3160104303 creator A5022486537 @default.
• W3160104303 creator A5026802293 @default.
• W3160104303 creator A5026975441 @default.
• W3160104303 creator A5028667213 @default.
• W3160104303 creator A5033142981 @default.
• W3160104303 creator A5035458931 @default.
• W3160104303 creator A5040843582 @default.
• W3160104303 creator A5042140133 @default.
• W3160104303 creator A5045281097 @default.
• W3160104303 creator A5056515618 @default.
• W3160104303 creator A5057489422 @default.
• W3160104303 creator A5058316873 @default.
• W3160104303 creator A5063217084 @default.
• W3160104303 creator A5063948431 @default.
• W3160104303 creator A5067202655 @default.
• W3160104303 creator A5069578834 @default.
• W3160104303 creator A5071128669 @default.
• W3160104303 creator A5080714302 @default.
• W3160104303 creator A5090302891 @default.
• W3160104303 creator A5090622636 @default.
• W3160104303 creator A5091292578 @default.
• W3160104303 date "2021-07-01" @default.
• W3160104303 modified "2023-10-16" @default.
• W3160104303 title "Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial" @default.
• W3160104303 cites W1986159244 @default.
• W3160104303 cites W2007777191 @default.
• W3160104303 cites W2050115670 @default.
• W3160104303 cites W2061731618 @default.
• W3160104303 cites W2079598348 @default.
• W3160104303 cites W2102061119 @default.
• W3160104303 cites W2141969865 @default.
• W3160104303 cites W2144957637 @default.
• W3160104303 cites W2145304413 @default.
• W3160104303 cites W2145453495 @default.
• W3160104303 cites W2151684406 @default.
• W3160104303 cites W2152800622 @default.
• W3160104303 cites W2158267770 @default.
• W3160104303 cites W2167273053 @default.
• W3160104303 cites W2331156573 @default.
• W3160104303 cites W2468171191 @default.
• W3160104303 cites W2508184004 @default.
• W3160104303 cites W2772087205 @default.
• W3160104303 cites W2801979411 @default.
• W3160104303 cites W2900490716 @default.
• W3160104303 cites W2927138762 @default.
• W3160104303 cites W3041333344 @default.
• W3160104303 cites W3044826209 @default.
• W3160104303 cites W3048823006 @default.
• W3160104303 cites W3073366168 @default.
• W3160104303 cites W3121373553 @default.
• W3160104303 doi "https://doi.org/10.1016/s2214-109x(21)00181-9" @default.
• W3160104303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34022150" @default.
• W3160104303 hasPublicationYear "2021" @default.
• W3160104303 type Work @default.
• W3160104303 sameAs 3160104303 @default.
• W3160104303 citedByCount "13" @default.
• W3160104303 countsByYear W31601043032021 @default.
• W3160104303 countsByYear W31601043032022 @default.
• W3160104303 countsByYear W31601043032023 @default.
• W3160104303 crossrefType "journal-article" @default.
• W3160104303 hasAuthorship W3160104303A5006925940 @default.
• W3160104303 hasAuthorship W3160104303A5007336043 @default.
• W3160104303 hasAuthorship W3160104303A5022486537 @default.
• W3160104303 hasAuthorship W3160104303A5026802293 @default.
• W3160104303 hasAuthorship W3160104303A5026975441 @default.
• W3160104303 hasAuthorship W3160104303A5028667213 @default.
• W3160104303 hasAuthorship W3160104303A5033142981 @default.
• W3160104303 hasAuthorship W3160104303A5035458931 @default.
• W3160104303 hasAuthorship W3160104303A5040843582 @default.
• W3160104303 hasAuthorship W3160104303A5042140133 @default.
• W3160104303 hasAuthorship W3160104303A5045281097 @default.
• W3160104303 hasAuthorship W3160104303A5056515618 @default.
• W3160104303 hasAuthorship W3160104303A5057489422 @default.
• W3160104303 hasAuthorship W3160104303A5058316873 @default.
• W3160104303 hasAuthorship W3160104303A5063217084 @default.
• W3160104303 hasAuthorship W3160104303A5063948431 @default.
• W3160104303 hasAuthorship W3160104303A5067202655 @default.
• W3160104303 hasAuthorship W3160104303A5069578834 @default.
• W3160104303 hasAuthorship W3160104303A5071128669 @default.
• W3160104303 hasAuthorship W3160104303A5080714302 @default.
• W3160104303 hasAuthorship W3160104303A5090302891 @default.
• W3160104303 hasAuthorship W3160104303A5090622636 @default.
• W3160104303 hasAuthorship W3160104303A5091292578 @default.
• W3160104303 hasBestOaLocation W31601043031 @default.
• W3160104303 hasConcept C126322002 @default.
• W3160104303 hasConcept C141071460 @default.
• W3160104303 hasConcept C203014093 @default.
• W3160104303 hasConcept C2522874641 @default.
• W3160104303 hasConcept C2776694085 @default.
• W3160104303 hasConcept C2776755627 @default.
• W3160104303 hasConcept C2777869810 @default.
• W3160104303 hasConcept C2778559949 @default.
• W3160104303 hasConcept C2778720950 @default.
• W3160104303 hasConcept C2779338263 @default.

• next